Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

DDM Holding AG and DDM Debt AB to report fourth quarter and full year 2019

DDM Holding AG (First North Growth Market: DDM) and its subsidiary DDM Debt AB (Nasdaq Stockholm: DDM2) will publish their Q4 and full year 2019 reports on Thursday 20 February 2020 at 08:00 CET. Mr. Henrik Wennerholm, CEO, and Mr. Fredrik Olsson, CFO, will host a conference call the same day, beginning at 10:00 CET, to present and comment on the DDM Group’sfinancial results. The conference will be held in English and can be followed live on www.ddm-group.ch  or by telephone with dial-in numbers: Sweden: +46 8 505 583 52 Switzerland:

DDM Holding AG and DDM Debt AB to report fourth quarter and full year 2019

DDM Holding AG (First North Growth Market: DDM) and its subsidiary DDM Debt AB (Nasdaq Stockholm: DDM2) will publish their Q4 and full year 2019 reports on Thursday 20 February 2020 at 08:00 CET. Mr. Henrik Wennerholm, CEO, and Mr. Fredrik Olsson, CFO, will host a conference call the same day, beginning at 10:00 CET, to present and comment on the DDM Group’sfinancial results. The conference will be held in English and can be followed live on www.ddm-group.ch  or by telephone with dial-in numbers: Sweden: +46 8 505 583 52 Switzerland:

Report on Operations 2019: High Time-lapse growth

Fourth quarter · Sales amounted to SEK 409 (320) million, corresponding to an increase of 28 percent in SEK. Sales increased by 21 percent in local currency whereof 11 percent comprised organic growth. · Operating income before depreciation and amortisation (EBITDA) amounted to SEK 160 (135) million, corresponding to a margin of 39 (42) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 7 million. · Net income amounted to SEK 96 (84) million, which gave earnings per share of SEK 0.89 (0.77). Whole year 2019 · Sales amounted to SEK 1 480 (1 151)

SenzaGen receives order of SEK 0.6 million from new global customer

SenzaGen will assess the sensitizing hazards of chemicals for a new global customer with in-house product development. The assignment includes SenzaGen's tests to assess whether chemical substances can cause allergic reactions in skin (GARD™skin) or in the respiratory tract (GARD™air) with a value of approximately SEK 0.6 million. The tests will be carried out at SenzaGen's laboratory in Lund.The customer has its headquarters in Europe where research and development have a central role. With the combination of GARD tests, the customer can for the first time identify substances with various

Invitation to presentation in conjunction with Net Gaming's Year-end Report 2019

On Thursday 20 February at 08:30 a.m. CET Net Gaming's Year-end Report 2019 will be published. At 10:00 a.m. the same day a presentation of Net Gaming's interim report for the fourth quarter and full year 2019, will be presented.CEO Marcus Teilman and CFO Gustav Vadenbring will present the results, followed by a Q&A session. The presentation will be held in English and will be webcasted live through netgaming.se or via https://tv.streamfabriken.com/net-gaming-europe-q4-2019 The join the conference via phone, please dial-in using any of the numbers below: From Sweden: +46856642695

Teleste to publish Financial Statement Release 2019 on 13th February 2020 - Invitation to press briefing

TELESTE CORPORATION           INVESTOR NEWS          6.2.2020  AT 09:30 EET TELESTE TO PUBLISH FINANCIAL STATEMENT RELEASE 2019 ON 13th FEBRUARY 2020 - INVITATION TO PRESS BRIEFING Teleste will publish its Financial Statement 1 January – 31 December 2019 as a stock exchange release on 13th February 2020 approx. at 08:30 a.m. EET. A briefing for investors, media and analysts will be held the same day in Helsinki hosted by the CEO, Mr. Jukka Rinnevaara. Teleste’s CFO, Mr. Juha Hyytiäinen will also be present in the briefing.  BRIEFING (held in Finnish):Date: Thursday, February

Climeon selected for H&M and WWF Cleantech Programme

Climeon has been selected to participate in the H&M and WWF Cleantech Programme for H&M suppliers. The programme aims at stimulating cleantech investments in the best available technologies to reduce emissions and costs in H&M’s supply chain. In 2019 H&M and WWF initiated a Cleantech Programme for the supply chain in cooperation with GloFin Advisory AB. The aim is to develop a cleantech financing programme with profitable solutions to H&M suppliers for implementation of clean technology. Several cleantech vendors have been evaluated within the framework of the programme before being

InCoax Networks AB’s Year-end Report, January–December 2019

Focusing the business strategy towards system design, with the goal that sales of our solutions will start to take off in 2020. We have 29 potential customers in test phase and are close to formalizing a project with great potential with one of the world’s largest operators, and are also in an intensified phase with another of the world’s largest operators.Financial performance October–December 2019 · Net sales amounted to SEK 576,547 (170,841), which is equivalent to an increase of 337% compared with the corresponding period in the preceding year. · The company posted an operating

Notice to the annual general meeting of Outotec Oyj

OUTOTEC OYJ   STOCK EXCHANGE RELEASE   FEBRUARY 6, 2020 at 9:15 AM Notice to the annual general meeting of Outotec Oyj Notice is given to the shareholders of Outotec Oyj (“Outotec”) to the Annual General Meeting to be held on Wednesday, March 11, 2020 at 12:00 noon (Finnish time) at Finlandia Hall, at the address Mannerheimintie 13e, FI-00100 Helsinki, Finland. The reception of persons who have registered for the Annual General Meeting and the distribution of voting tickets will commence at the venue at 11:00 a.m. A. MATTERS ON THE AGENDA OF THE ANNUAL GENERAL MEETING 1. Opening

The Board of Directors of Konecranes Plc decided to continue the Employee Share Savings Plan

KONECRANES PLC  STOCK EXCHANGE RELEASE February 6, 2020 at 9:10The Board of Directors of Konecranes Plc decided to continue the Employee Share Savings PlanKonecranes Plc’s Annual General Meeting of Shareholders 2012 decided to implement an Employee Share Savings Plan (the Plan) in the Konecranes Group.On the basis of interest shown by the Group employees, the Board has decided to launch a new Plan Period. The new plan period will begin on July 1, 2020 and end on June 30, 2021. The maximum savings amount per participant during one month is 5 percent of gross salary and the minimum is

Konecranes announces changes to its Leadership Team

Konecranes announces changes to its Leadership Team Konecranes today appointed Carolin Paulus Executive Vice President for the Industrial Equipment Business Area effective March 1, 2020. She will report to Konecranes President and CEO Rob Smith and join the Konecranes Leadership Team.Paulus, 51, currently Senior Vice President for Global Parts & Service Procurement, will transition duties with Mikko Uhari, 62, who has led the Industrial Equipment Business Area since 2016, during February in line with Konecranes succession and retirement planning process. Uhari will take the project

Citycon Board’s asset distribution proposal to the Annual General Meeting

CITYCON OYJ   Stock Exchange Release   6 February 2020 at 09:05 hrsThe Board of Directors of Citycon Oyj has decided to propose to the Annual General Meeting to be held on 17 March 2020 of the asset distribution as follows. The Board of Directors proposes that based on the balance sheet to be adopted for the financial period ended on 31 December 2019, no dividend is distributed by a resolution of the Annual General Meeting. Nonetheless, the Board of Directors proposes that the Board of Directors be authorized to decide in its discretion on the distribution of dividend and assets from

Citycon Oyj updates its guidance policy following the issuance of Capital Securities

CITYCON OYJ   Stock Exchange Release   6 February 2020 at 09.05 hrsCitycon’s Board of Directors has resolved to update Citycon’s guidance policy following the issuance of Subordinated Capital Securities (“hybrid bond”). In order to quantify the impact of hybrid bond coupons, Citycon will also provide guidance on adjusted EPRA EPS after hybrid bond coupon payments. As of 2020, Citycon will provide guidance on direct operating profit, EPRA EPS and adjusted EPRA EPS. Citycon announced on 18 November 2019 that it issued EUR 350 million green hybrid bond with an issue date of 22 November 2019.

Termination of personnel share savings plan – change in Outotec Oyj treasury shares

OUTOTEC OYJ   STOCK EXCHANGE RELEASE   FEBRUARY 6, 2020 at 9:05 AM Termination of personnel share savings plan – change in Outotec Oyj treasury shares Outotec's Board of Directors has on February 5, 2020 decided to terminate the Employee Share Savings Plan (O’Share) and on an early settlement of free shares in the pending O’Share 2017, 2018 and 2019 saving periods by a conveyance of existing Outotec shares held by the company. The decision is related to the expected merger of Outotec and Metso. An estimated number of 215,000 shares up to the maximum of 430,000 treasury shares of

Mandatory notification of trade

Reference is made to the stock exchange announcement by Axactor SE regarding the private placement of 30 million new shares. Geveran Trading Co Ltd,  a company indirectly controlled by trusts established by Mr. John Fredriksen for the benefit of his immediate family, was allocated 12,000,000 shares in the private placement at NOK 17.25 per share. Following completion of the private placement, Geveran Trading Co Ltd. will own 56,710,233 shares in Axactor, representing 30.59 % of the outstanding share capital and voting rights in the Company.

Year-End Report 1 January – 31 December 2019

”Strong ending of the year” 1 OCTOBER – 31 DECEMBER 2019 (3 MONTHS) · Net sales increased by 44 percent to SEK 988 million (685), of which organic growth amounted to 8 percent and acquired growth amounted to 35 percent. · EBITA increased by 39 percent to SEK 102 million (74), corresponding to an EBITA-margin of 10.4 percent (10.8). · Profit after tax increased by 12 percent to SEK 49 million (44). · Earnings per share amounted to SEK 1.76 (1.83). · Cash flow from operating activities amounted to SEK 175 million (92), including IFRS 16 effect of SEK 22 million (0). 1

BioGaia AB – Year-end report 2019

Comments from the CEO:“Sales in the fourth quarter of 2019 decreased by 1%, mainly due to reduced royalties from Nestlé and delivery problems. Product sales increased by 6% due to favourable growth primarily for the Paediatrics segment with a sales growth of 10%. The operating margin reached 33% despite lower sales and our increased investments in the subsidiaries MetaboGen and BioGaia Pharma.  “We started the year knowing that Nestlé had terminated the royalty agreement for Growing Up Milk and we understood that it would be difficult to achieve our normal growth rate. The plan to

I-Tech customer receives Nikkei Business Daily Awards for Excellence award for Selektope®-powered antifouling coating.

I-Tech AB’s (publ) (ticker: ITECH) largest customer, Chugoku Marine Paints, Ltd, has received prestigious recognition from the Nikkei Business Daily Awards for Excellence for their SEA PREMIER 3000 PLUS antifouling coating which is based on I-Tech’s revolutionary, barnacle-repelling active agent Selektope®.Gothenburg, Sweden – 6 February 2020: The Selektope®-powered antifouling SEA PREMIER 3000 PLUS has been recognised by the Nikkei Business Daily Awards for Excellence, in the Superior Products and Services Award category. The Nikkei is the largest financial newspaper in Japan. Now in

Hansa Biopharma Year-End Report 2019

Solid advancements in our pipeline. Agreement on a clear regulatory path with the FDA; EMA process on trackHighlights for the fourth quarter 2019 -    The ongoing review of an MAA for imlifidase in Europe by EMA is on track. Responses to the Day 120 questions were submitted on December 20, 2019. An opinion from the CHMP is expected in the second quarter of 2020.  -    Reached agreement with the FDA on a regulatory path forward for imlifidase in kidney transplantation of highly sensitized patients in the U.S. Hansa will conduct a randomized, controlled clinical study in a well-defined

Midsona - Year-end Report 2019

Strong cash flow with good underlying growth in the businessOctober–December 2019 (fourth quarter) · Net sales amounted to SEK 825 million (755), of which the concluded Alpro sales assignment was SEK 2 million (63). · EBITDA amounted to SEK 81 million (59) before items affecting comparability, corresponding to a margin of 9.8 percent (7.8). · Profit for the period amounted to SEK 35 million (33), corresponding to earnings per share of SEK 0.64 (0.71) before and after dilution. · Free cash flow amounted to SEK 103 million (44). · Midsona gained control of the acquired

Year-end Report, January-December 2019

Strong development of order intake, net sales and EBIT “I am pleased today to present another successful year for Mycronic, particularly in light of the global unrest and the slowdown in the electronics industry that characterized 2019. Order intake amounted to SEK 4,567 million, up 25 percent compared with the previous record year of 2018. In parallel, net sales increased 14 percent to SEK 4,307 million, with positive currency effects of SEK 171 million. EBIT rose 10 percent to SEK 1,124 million, with both business areas contributing to the improvement,” says Anders Lindqvist, President

Full Year Report for the period January – December 2019

Enhanced project portfolio from a successful yearKey events during the fourth quarter 2019 · BioArctic initiated a research collaboration with Eisai aimed at further studying the unique profile of the drug candidate BAN2401 · BioArctic strengthened its management team with two strategic recruitments · BioArctic and Eisai presented data on the drug candidate BAN2401 at the international CTAD conference (Clinical Trials on Alzheimer’s Disease) in San Diego · BioArctic announced results from the interim analysis of the Phase 1/2 study with SC0806, a potential treatment for

Lower organic growth with strong profit and cash flow

Fourth quarter · Net sales increased by 8% to SEK 24,946 M (23,167), with organic growth of 1% (6) and acquired net growth of 3% (3) · Strong organic growth in Americas, good growth in Global Technologies and stable in EMEA and Entrance Systems, while sales declined in Asia Pacific · Two acquisitions signed with expected combined annual sales of SEK 800 M · Tax decision in Finland reconsidered to ASSA ABLOY’s disadvantage. Estimated tax exposure of SEK 920 M, but no material effect on the Group’s net income · Operating income[1] (EBIT)[ ]increased by 8% and amounted to SEK

Traumakine update

Faron Pharmaceuticals Oy ("Faron" or the "Company")   Traumakine update  -     New trial protocol preventing concomitant corticosteroid use with Traumakine -     Company notes WHO recommendations on use of steroids in coronavirus patients   Company announcement, 06 February 2020 at 9.00 AM (EET)Inside information TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today provides an update on Traumakine's clinical continuation following a meeting with the U.S. Food and Drug Administration (FDA) in

There are no items matching the current filter
There are no more items matching the current filter
Back to top